Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
Rituximab in the treatment of autoimmune haematological disorders
Article first published online: 3 MAR 2008
© 2008 The Author
British Journal of Haematology
Volume 141, Issue 2, pages 149–169, April 2008
How to Cite
Garvey, B. (2008), Rituximab in the treatment of autoimmune haematological disorders. British Journal of Haematology, 141: 149–169. doi: 10.1111/j.1365-2141.2008.07054.x
- Issue published online: 18 MAR 2008
- Article first published online: 3 MAR 2008
- acquired haemophilia;
- autoimmune haemolytic anaemia;
- cold agglutinin disease;
- idiopathic thrombocytopenic purpura;
- thrombotic thrombocytopenic purpura
Current treatment regimens for haematological autoimmune diseases are relatively non-selective and are often associated with considerable toxicity. Recently, it has become clear that B cells play a key role in both the development and perpetuation of autoimmunity, suggesting that B-cell depletion could be a valuable treatment approach for patients with autoimmune diseases. This article reviews data supporting the use of rituximab – an anti-CD20 monoclonal antibody that specifically depletes B cells – in four key autoimmune haematological disorders: idiopathic thrombocytopenic purpura (ITP); autoimmune haemolytic anaemia (AIHA); acquired haemophilia; and thrombotic thrombocytopenic purpura (TTP). Although treatment of ITP, AIHA, acquired haemophilia and TTP with rituximab is still relatively uncommon, results from case series and small phase II trials indicate that patients of all ages can respond to rituximab, irrespective of the number or type of prior treatments that they have received. Moreover, patients with these diseases receiving rituximab experienced predominantly mild adverse events, with only a few serious adverse events reported. These data suggest that rituximab provides an effective and well-tolerated alternative treatment option for patients with ITP, AIHA, acquired haemophilia and TTP, many of whom have limited treatment choices.